CME Information
Provider Statement
This continuing medical education activity is provided by 
.
Support Statement
This activity is supported by an educational grant from Genentech, Inc.
Association/Society Statement
Endorsed by Kiawah Eye.
Target Audience
The intended audience for this activity is ophthalmologists, retina specialists, and other health care professionals involved in the management of patients with neovascular retinal disorders.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Evaluate new evidence on emerging approaches in drug delivery and gene therapy for the treatment of neovascular retinal diseases.
- Summarize emerging advances that allow for the targeting of treatment in neovascular retinal diseases.
Faculty
Carl D. Regillo, MD, FACS
Director, Wills Eye Retina Service
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA
Nathan C. Steinle, MD
California Retina Consultants
Santa Barbara, CA
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which is defined as answering ALL the posttest questions and includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.
This enduring material is approved for 1 year from the date of original release, October 20, 2020, through October 19, 2021.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 3 of 4 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.
Faculty members report the following relationship(s)
Carl D. Regillo, MD, FACS
Consulting Fee:
Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug Vision, Kodiak, Merck, Notal Vision, Novartis, Takeda
Contracted Research:
Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug Vision, Kodiak, Notal Vision, Novartis, Regeneron, Regenxbio
Nathan C. Steinle, MD
Consulting Fee: Alimera, Allergan, Genentech, Novartis, Regeneron
Speakers Bureau: Alimera, Genentech, Novartis, Regeneron
Contracted Research:
Alimera, Genentech, Novartis, Regeneron
Ownership Interest:
Vortex Surgery
Reviewer reports the following relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com